A recent clinical study focused on treating CD19+ non-Hodgkin’s lymphoma and chronic lymphocytic leukemia through the infusion of retrovirus-transduced anti-CD19 CAR cord blood NK cells. This evidence concerns the gene CD19 and B-cell chronic lymphocytic leukemia.